DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2020</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>April 2018</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>September 1992</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P. (Lead)  Lisa Ingerman, Ph.D., D.A.B.T.
Obaid Faroon, D.V.M., Ph.D.    Julie M. Klotzbach, Ph.D.
Mike Fay, Ph.D.                Christina Coley, B.S.

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; U.S. EPA.

PEER REVIEWERS

1. Kelly A. Reynolds, Ph.D., Zuckerman College of Public Health Program, The University of Arizona, Tucson, Arizona
2. Kyle Steenland, Ph.D., Rollins School of Public Health at Emory, Atlanta, Georgia
3. Prakash Mulay, MBBS, MPH, Florida Department of Health, Tallahassee, Florida

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
CONTENTS

DISCLAIMER ........................................................................................................................................ ii
FOREWORD ........................................................................................................................................ iii
VERSION HISTORY ............................................................................................................................ v
CONTRIBUTORS & REVIEWERS ....................................................................................................... vi
CONTENTS .......................................................................................................................................... vii
LIST OF FIGURES .............................................................................................................................. ix
LIST OF TABLES .................................................................................................................................... x

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH .............................................................................. 1
  1.1 OVERVIEW AND U.S. EXPOSURES ....................................................................................... 1
  1.2 SUMMARY OF HEALTH EFFECTS ....................................................................................... 1
  1.3 MINIMAL RISK LEVELS (MRLs) ............................................................................................ 6

CHAPTER 2. HEALTH EFFECTS ........................................................................................................ 9
  2.1 INTRODUCTION ..................................................................................................................... 9
  2.2 DEATH ..................................................................................................................................... 37
  2.3 BODY WEIGHT ....................................................................................................................... 38
  2.4 RESPIRATORY ...................................................................................................................... 39
  2.5 CARDIOVASCULAR ............................................................................................................... 41
  2.6 GASTROINTESTINAL .......................................................................................................... 41
  2.7 HEMATOLOGICAL ................................................................................................................ 43
  2.8 MUSCULOSKELETAL ............................................................................................................ 43
  2.9 HEPATIC .................................................................................................................................. 44
  2.10 RENAL .................................................................................................................................... 44
  2.11 DERMAL .................................................................................................................................. 45
  2.12 OCULAR .................................................................................................................................. 46
  2.13 ENDOCRINE ....................................................................................................................... 46
  2.14 IMMUNOLOGICAL .............................................................................................................. 47
  2.15 NEUROLOGICAL ................................................................................................................ 47
  2.16 REPRODUCTIVE ................................................................................................................ 54
  2.17 DEVELOPMENTAL .......................................................................................................... 55
  2.18 CANCER ............................................................................................................................. 56
  2.19 GENOTOXICITY .................................................................................................................. 58
  2.20 MECHANISMS OF TOXICITY ........................................................................................... 60

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS .......................................................................................................................... 62
  3.1 TOXICOKINETICS ............................................................................................................. 62
     3.1.1 Absorption ...................................................................................................................... 62
     3.1.2 Distribution .................................................................................................................... 63
     3.1.3 Metabolism ................................................................................................................... 64
     3.1.4 Excretion ....................................................................................................................... 65
     3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ....... 66
     3.1.6 Animal-to-Human Extrapolations ............................................................................... 67
  3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ......... 67
  3.3 BIOMARKERS OF EXPOSURE AND EFFECT .................................................................. 68
     3.3.1 Biomarkers of Exposure .............................................................................................. 69
LIST OF FIGURES

1-1. Health Effects in Animals Following Inhalation Exposure to Bromomethane ......................... 3
1-2. Health Effects in Animals Following Oral Exposure to Bromomethane ................................. 4
1-3. Summary of Sensitive Targets of Bromomethane – Inhalation ................................................. 8
2-1. Overview of the Number of Studies Examining Bromomethane Health Effects .................... 12
2-2. Levels of Significant Exposure to Bromomethane – Inhalation ............................................. 25
2-3. Levels of Significant Exposure to Bromomethane – Oral ....................................................... 34
5-1. Number of NPL Sites with Bromomethane Contamination ..................................................... 74
6-1. Summary of Existing Health Effects Studies on Bromomethane by Route and Endpoint ...... 104
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Bromomethane ................................................................. 7

2-1. Levels of Significant Exposure to Bromomethane – Inhalation........................................... 13

2-2. Levels of Significant Exposure to Bromomethane – Oral..................................................... 31

2-3. Genotoxicity of Bromomethane In Vitro............................................................................. 58

2-4. Genotoxicity of Bromomethane In Vivo ............................................................................. 59

4-1. Chemical Identity of Bromomethane.................................................................................. 72

4-2. Physical and Chemical Properties of Bromomethane........................................................ 72

5-1. Facilities that Produce, Process, or Use Bromomethane ...................................................... 76

5-2. U.S. Companies Manufacturing Bromomethane.................................................................. 77

5-3. Bromomethane Inventory in the United States from 2003 to 2014 .................................... 79

5-4. Releases to the Environment from Facilities that Produce, Process, or Use Bromomethane. 82

5-5. Estimated Anthropogenic and Natural Sources of Bromomethane (Gg/Year) 1996–1998 and 2008 ........................................................................................................ 84

5-6. Lowest Limit of Detection Based on Standards ............................................................... 93

5-7. Summary of Environmental Levels of Bromomethane .................................................... 94

5-8. Bromomethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites ........ 94

5-9. Percentile Distribution of Annual Mean Bromomethane Concentrations (ppbv) Measured in Ambient Air at Locations Across the United States ........................................ 95

5-10. Ambient Air Concentrations in Parts per Billion Near Areas of Bromomethane Use .... 96

5-11. Bromomethane Levels Following Fumigation .................................................................. 97

7-1. Regulations and Guidelines Applicable to Bromomethane.................................................. 112